Therapeutic plasma exchange: An update from the Canadian Apheresis Group

Annals of Internal Medicine

Volumn 131, Issue 6, 1999, Pages 453-462

  Clark, William F ^a   Rock, Gail A ^b   Buskard, Noel ^c   Shumak, Kenneth H ^d   LeBlond, Pierre ^e   Andersen, David ^f   Sutton, David M ^g  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; GUILLAIN BARRE SYNDROME; HUMAN; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0033592442     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-6-199909210-00011     Document Type: Article

References (21)

1. Rock GA, Shumak KH, Buskard NA. Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-7.
2. Cole E, Cattran D. Magil A, Greenwood C, Churchill D, Sutton D, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. 1992;20:261-9.
3. The Canadian cooperative trial of cydophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet. 1991;337:441-6.
4. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119(Pt 4): 1055-66.
5. Clark WF, Dau PC, Euler HH, Guillevin L, Hasford J, Heer AH. et al. Plasmapheresis and subsequent pulse cydophosphamide versus pulse cydophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG). J Clin Apheresis. 1991;6:40-7.
6. Henon PR. Treatment of thrombotic thrombocytopenic purpura. First results of a controlled clinical trial. Plasma Therapy Transfusion Technology. 1986;7:101-6.
7. The use of therapeutic plasmapheresis for neurological disorders. National Institutes of Health Consensus Development Conference. Transfus Med Rev. 1988;2:48-53.
8. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789-96.
9. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461-5.
10. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838-45.
11. Plasmapheresis and acute Guillain Barré syndrome. The Guillain Barré Syndrome Study Group. Neurology. 1985;35:1096-104.
12. Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol. 1997;41:298-306.
13. van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326:1123-9.
14. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997;349:225-30.
15. Dwosh IL, Giles AR, Ford PM, Pater JL. Anastassiades TP. Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial. N Engl J Med. 1983;308:1124-9.
16. Wei N, Klippel JH, Huston DP, Hall RP, Lawley TJ, Balow JE, et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet. 1983;1:17-22.
17. Clark WF, Balfe JW, Cattran DC, Williams W, Koval JJ, Arnott P, et al. Long term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis. Plasma Therapy Transfusion Technology. 1984;5:353-60.
18. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992;326:1373-9.
19. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum. 1994;37:1784-94.
20. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;303:173-80.
21. Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffman RG. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology. 1985;35:312-9.